Chlorzoxazone as a single sample probe of hepatis CYP2E1 activity in humans

被引:27
作者
Bachmann, K [1 ]
Sarver, JG [1 ]
机构
[1] UNIV TOLEDO,CTR DRUG DESIGN & DEV,TOLEDO,OH 43606
关键词
chlorzoxazone; clearance; single sample clearance; CYP2E1;
D O I
10.1159/000139381
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of this investigation was to determine whether the oral clearance (CL) of chlorzoxazone could be estimated accurately from a single plasma chlorzoxazone measurement. In 6 healthy male subjects the mean clearance estimate (CL(est)) from a single 6-hour postdose measurement of plasma chlorzoxazone was within 6% of the actual mean CL calculated conventionally from the area under the plasma concentration versus time curve (AUG). After a second dose of chlorzoxazone administered I week later, the 6-hour mean CL(est) was within approximately 10% of the value from the previous week and within 15% of the value of CL from the previous week, No significant differences occurred between these three clearances, suggesting that for purposes of phenotyping CYP2E1 activity in humans with chlorzoxazone, a single-dose, single-sample procedure may suffice.
引用
收藏
页码:169 / 177
页数:9
相关论文
共 20 条
  • [1] USE OF SINGLE SAMPLE CLEARANCE ESTIMATES OF CYTOCHROME-P450 SUBSTRATES TO CHARACTERIZE HUMAN HEPATIC CYP STATUS INVIVO
    BACHMANN, KA
    JAUREGUI, L
    [J]. XENOBIOTICA, 1993, 23 (03) : 307 - 315
  • [2] A MINIMAX APPROACH TO THE SINGLE-POINT METHOD OF DRUG DOSING
    BAHN, MM
    LANDAW, EM
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1987, 15 (03): : 255 - 269
  • [3] THE PROCARCINOGEN HYPOTHESIS FOR BLADDER-CANCER - ACTIVITIES OF INDIVIDUAL-DRUG METABOLIZING ENZYMES AS RISK-FACTORS
    BRANCH, RA
    CHERN, HD
    ADEDOYIN, A
    ROMKESSPARKS, M
    LESNICK, TG
    PERSAD, R
    WILKINSON, GR
    FLEMING, CM
    DICKINSON, AJ
    SIBLEY, G
    SMITH, P
    [J]. PHARMACOGENETICS, 1995, 5 : S97 - S102
  • [4] BOTH CYTOCHROMES P450 2E1 AND 1A1 ARE INVOLVED IN THE METABOLISM OF CHLORZOXAZONE
    CARRIERE, V
    GOASDUFF, T
    RATANASAVANH, D
    MOREL, F
    GAUTIER, JC
    GUILLOUZO, A
    BEAUNE, P
    BERTHOU, F
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 1993, 6 (06) : 852 - 857
  • [5] A SIMPLE METHOD FOR DETERMINATION OF ANTIPYRINE CLEARANCE
    DOSSING, M
    POULSEN, HE
    ANDREASEN, PB
    TYGSTRUP, N
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 32 (03) : 392 - 396
  • [6] DOSSING M, 1983, BR J CLIN PAHRM, V15, P321
  • [7] Gibaldi M, 1982, PHARMACOKINETICS, P433
  • [8] ASSESSMENT OF CYTOCHROME P4502E1 INDUCTION IN ALCOHOLIC PATIENTS BY CHLORZOXAZONE PHARMACOKINETICS
    GIRRE, C
    LUCAS, D
    HISPARD, E
    MENEZ, C
    DALLY, S
    MENEZ, JF
    [J]. BIOCHEMICAL PHARMACOLOGY, 1994, 47 (09) : 1503 - 1508
  • [9] CYTOCHROME P4502E1 (CYP2E1) GENETIC-POLYMORPHISM IN A CASE-CONTROL STUDY OF GASTRIC-CANCER AND LIVER-DISEASE
    KATO, S
    ONDA, M
    MATSUKURA, N
    TOKUNAGA, A
    TAJIRI, T
    KIM, DY
    TSURUTA, H
    MATSUDA, N
    YAMASHITA, K
    SHIELDS, PG
    [J]. PHARMACOGENETICS, 1995, 5 : S141 - S144
  • [10] SINGLE-DOSE DISULFIRAM INHIBITION OF CHLORZOXAZONE METABOLISM - A CLINICAL PROBE FOR P450-2E1
    KHARASCH, ED
    THUMMEL, KE
    MHYRE, J
    LILLIBRIDGE, JH
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (06) : 643 - 650